NALIRIFOX versus nab-paclitaxel and gemcitabine in treatment-naive patients with metastatic pancreatic ductal adenocarcinoma (NAPOLI 3): a randomised, open-label, phase 3 trial
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Erschienen in
-
In: The Lancet, 402.2023, 10409, S. 1272-1281
- Ereignis
-
Veröffentlichung
- (wo)
-
Frankfurt am Main
- (wer)
-
Universitätsbibliothek Johann Christian Senckenberg
- (wann)
-
2023
- Urheber
-
Wainberg, Zev A.
Melisi, Davide
Macarulla, Teresa
Pazo Cid, Roberto
Chandana, Sreenivasa R.
De La Fouchardière, Christelle
Dean, Andrew
Kiss, Igor
Jin Lee, Woo
Götze, Thorsten
Van Cutsem, Eric
Paulson, A. Scott
Bekaii-Saab, Tanios
Pant, Shubham
Hubner, Richard A.
Xiao, Zhimin
Chen, Huanyu
Benzaghou, Fawzi
O'Reilly, Eileen M.
- DOI
-
10.1016/S0140-6736(23)01366-1
- URN
-
urn:nbn:de:hebis:30:3-791275
- Rechteinformation
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
25.03.2025, 13:52 MEZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Wainberg, Zev A.
- Melisi, Davide
- Macarulla, Teresa
- Pazo Cid, Roberto
- Chandana, Sreenivasa R.
- De La Fouchardière, Christelle
- Dean, Andrew
- Kiss, Igor
- Jin Lee, Woo
- Götze, Thorsten
- Van Cutsem, Eric
- Paulson, A. Scott
- Bekaii-Saab, Tanios
- Pant, Shubham
- Hubner, Richard A.
- Xiao, Zhimin
- Chen, Huanyu
- Benzaghou, Fawzi
- O'Reilly, Eileen M.
- Universitätsbibliothek Johann Christian Senckenberg
Entstanden
- 2023
Ähnliche Objekte (12)
Pankreaskarzinom nab-Paclitaxel
Breast cancer nab-Paclitaxel
MicroRNA Profiling Implies New Markers of Gemcitabine Chemoresistance in Mutant p53 Pancreatic Ductal Adenocarcinoma
COL8A1 promotes progression and gemcitabine resistance of pancreatic ductal adenocarcinoma through an autocrine/paracrine fashion
Gemcitabine and nab-paclitaxel combined with afatinib in metastatic pancreatic cancer – Results of a phase 1b clinical trial
Gemcitabine/nab-paclitaxel versus FOLFIRINOX for palliative first-line treatment of advanced pancreatic cancer: a propensity score analysis
Advanced pancreatic ductal adenocarcinoma : moving forward
Characterization of dexamethasone-induced gemcitabine resistance, cancer stem cell properties and epithelial-mesenchymal transition in pancreatic ductal adenocarcinoma
Nab-Paclitaxel beim NSCLC : therapeutischer Stellenwert von Nab-Paclitaxel in der Therapie des nicht kleinzelligen Lungenkarzinoms (NSCLC)
Intensified neoadjuvant chemotherapy with nab-paclitaxel plus gemcitabine followed by FOLFIRINOX in a patient with locally advanced unresectable pancreatic cancer
Editorial: Translational Insights Into Pancreatic Ductal Adenocarcinoma
An immunological glance on pancreatic ductal adenocarcinoma
Pankreaskarzinom nab-Paclitaxel
Breast cancer nab-Paclitaxel
MicroRNA Profiling Implies New Markers of Gemcitabine Chemoresistance in Mutant p53 Pancreatic Ductal Adenocarcinoma
COL8A1 promotes progression and gemcitabine resistance of pancreatic ductal adenocarcinoma through an autocrine/paracrine fashion
Gemcitabine and nab-paclitaxel combined with afatinib in metastatic pancreatic cancer – Results of a phase 1b clinical trial
Gemcitabine/nab-paclitaxel versus FOLFIRINOX for palliative first-line treatment of advanced pancreatic cancer: a propensity score analysis
Advanced pancreatic ductal adenocarcinoma : moving forward
Characterization of dexamethasone-induced gemcitabine resistance, cancer stem cell properties and epithelial-mesenchymal transition in pancreatic ductal adenocarcinoma
Nab-Paclitaxel beim NSCLC : therapeutischer Stellenwert von Nab-Paclitaxel in der Therapie des nicht kleinzelligen Lungenkarzinoms (NSCLC)
Intensified neoadjuvant chemotherapy with nab-paclitaxel plus gemcitabine followed by FOLFIRINOX in a patient with locally advanced unresectable pancreatic cancer
Editorial: Translational Insights Into Pancreatic Ductal Adenocarcinoma
An immunological glance on pancreatic ductal adenocarcinoma
Pankreaskarzinom nab-Paclitaxel
Breast cancer nab-Paclitaxel
MicroRNA Profiling Implies New Markers of Gemcitabine Chemoresistance in Mutant p53 Pancreatic Ductal Adenocarcinoma
COL8A1 promotes progression and gemcitabine resistance of pancreatic ductal adenocarcinoma through an autocrine/paracrine fashion
Gemcitabine and nab-paclitaxel combined with afatinib in metastatic pancreatic cancer – Results of a phase 1b clinical trial
Gemcitabine/nab-paclitaxel versus FOLFIRINOX for palliative first-line treatment of advanced pancreatic cancer: a propensity score analysis
Advanced pancreatic ductal adenocarcinoma : moving forward
Characterization of dexamethasone-induced gemcitabine resistance, cancer stem cell properties and epithelial-mesenchymal transition in pancreatic ductal adenocarcinoma
Nab-Paclitaxel beim NSCLC : therapeutischer Stellenwert von Nab-Paclitaxel in der Therapie des nicht kleinzelligen Lungenkarzinoms (NSCLC)
Intensified neoadjuvant chemotherapy with nab-paclitaxel plus gemcitabine followed by FOLFIRINOX in a patient with locally advanced unresectable pancreatic cancer
Editorial: Translational Insights Into Pancreatic Ductal Adenocarcinoma